Evaluating a new vaccine for shingles in adults aged 40 and older
A Phase I, Randomized, Observer-blinded, Parallel-Controlled, Dose Escalation Clinical Trial to Assess the Safety and Immunogenicity of the Recombinant Zoster Vaccine, LYB004 in Adults Aged 40 Years and Older
This study is testing a new shingles vaccine in healthy adults aged 40 and older to see if it's safe and effective.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Enrollment | 92 (estimated) |
| Ages | 40 Years and up |
| Sex | All |
| Sponsor | Guangzhou Patronus Biotech Co., Ltd. Industry-sponsored |
| Drugs / interventions | prednisone |
| Locations | 1 site (Meizhou) |
| Trial ID | NCT06874842 on ClinicalTrials.gov |
What this trial studies
This phase 1 trial in China aims to assess the safety and immunogenicity of the Recombinant Zoster Vaccine, LYB004, in adults aged 40 years and older. The study will enroll 92 healthy participants, stratified by age, and will utilize a randomized, observer-blinded, positive-controlled, dose escalation design. Participants will receive different formulations of the vaccine, including varying doses of antigen and adjuvant, with close monitoring for safety. The trial will include six cohorts, with a sentinel dosing approach to minimize risk.
Who should consider this trial
Good fit: Ideal candidates for this study are healthy adults aged 40 years and older.
Not a fit: Patients with a history of severe allergic reactions to vaccines or those with compromised immune systems may not benefit from this study.
Why it matters
Potential benefit: If successful, this vaccine could provide effective protection against shingles for older adults.
How similar studies have performed: Other studies have shown success with similar vaccine approaches for herpes zoster, indicating potential for positive outcomes.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Residents aged 40 years and older (at the time of screening), regardless of gender; 2. Participants can provide valid identification, voluntarily agree to participate in the study, and sign the Informed Consent Form; 3. Participants are able to attend all planned follow-up visits and comply with the protocol requirements; 4. Females of childbearing potential should use effective contraceptive measures one month before enrollment; females of childbearing potential (excluding those who have undergone tubal ligation, bilateral oophorectomy, or hysterectomy) and male participants should practice effective contraception and avoid pregnancy plans, as well as sperm or egg donation plans from the time of enrollment until 6 months after the full course of vaccination. Effective contraceptive methods include oral contraceptives (excluding emergency contraceptives), injectable or implantable contraceptives, sustained-release local contraceptives, contraceptive patches, intrauterine devices, sterilization, abstinence, condoms, diaphragms, cervical caps, etc. Exclusion Criteria: 1. Axillary temperature ≥ 37.3°C; 2. History of herpes zoster before vaccination with the investigational vaccine; 3. Previous vaccination against HZ or varicella; 4. Has had close contact with patients with varicella/herpes zoster within 6 months before vaccination with the investigational vaccine; 5. Has received any vaccine within 14 days before vaccination, or have received a live vaccine within 28 days; 6. Have been injected with gamma globulin or intravenous immunoglobulin within 3 months before vaccination; 7. Individual with the following diseases: ① Have acute diseases or are in the acute exacerbation period of chronic diseases, or take antipyretic, analgesic, and anti-allergic drugs within 3 days before vaccination; ② Allergies to any component of the study vaccine, or have a history of severe allergic reactions to any vaccination; ③ History of convulsions, epilepsy, encephalopathy (such as congenital brain dysplasia, brain trauma, brain tumors, cerebral hemorrhage, cerebral infarction, brain infection, chemical poisoning, etc. causing brain nerve tissue damage, etc.) and mental illness, or a family history of mental illness; ④ Asplenia, or functional asplenia; ⑤Primary or secondary immunodeficiency, or diagnosed with congenital or acquired immunodeficiency, human immunodeficiency virus infection, lymphoma, leukemia, systemic lupus erythematosus, rheumatoid arthritis, juvenile rheumatoid arthritis, inflammatory bowel disease, or other autoimmune diseases; ⑥ Chronic administration (≥14 consecutive days) of glucocorticoid (reference value for dose: ≥ 2mg/kg/day or ≥ 20mg/day prednisone or equivalent) or other immunosuppressive agents within the past 3 months, with the exception of inhaled or topical steroids, or short-term use (\<14 consecutive days) of oral corticosteroids; ⑦ Severe cardiovascular diseases (pulmonary heart disease, pulmonary edema, etc.), severe liver and kidney diseases, complicated diabetes; ⑧ History of thrombocytopenia or other coagulation disorders that may contraindicate intramuscular injection;⑨Severe hypertension that cannot be controlled by medication (on-site measurement: systolic blood pressure ≥ 140mmHg and/or diastolic blood pressure ≥ 90mmHg); 8. Abnormal laboratory test indicators specified in the protocol before vaccination and determined by the clinical investigator to be of clinical significance; 9. History of long-term alcohol abuse and/or drug abuse; 10. Individual who is currently participating in other research or unregistered product (drugs, vaccines, or devices, etc.) clinical studies, or plan to participate in other clinical studies before the end of this clinical study; 11. Exclusion criteria for specific populations: lactating or pregnant women during the clinical research period, or women of childbearing age with a positive pregnancy test before vaccination; 12. Other conditions that may impact the subject's safety or influence the assessment of vaccine response, as determined by the investigator.
Where this trial is running
Meizhou
- Guangdong Provincial Center for Disease Control and Prevention — Meizhou, China (Recruiting)
Study contacts
- Principal investigator: Renfeng Fan — Guangdong Center for Disease Prevention and Control
- Study coordinator: Renfeng Fan
- Email: gdsjkzx_sws_sps@gd.gov.cn
- Phone: 8613560231815
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.